Needham & Company initiates coverage on CONMED (NASDAQ: CNMD) with a Buy. PT $37.00.

Analyst Mike Matson comments, "CNMD ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE